ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Roivant Sciences Ltd.
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$34.70+1.17 (+3.49%)
Close on Oct 19, 2026
- Market cap
- $25.01B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$17.44 (+101.0%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Roivant Sciences Ltd. saw revenue fall 67.6% to $7.53M over the twelve months to Jun 30, 2026. Free cash flow was -$821.06M.
Revenue
$7.53M
-67.6% vs. a year earlier
Operating income
-$596.14M
TTM Q1 2026
Free cash flow
-$821.06M
TTM Q1 2026
EPS, diluted
-$0.39
TTM Q1 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $25.01B
- P/E ratio
- –
- Price to sales
- 3320.63
- Price to book
- 5.91
- Dividend yield
- –
- Free cash flow yield
- -3.28%
Fundamentals
- Revenue
- $7.53M
- Net income
- -$266.25M
- EPS, diluted
- -$0.39
- Free cash flow
- -$821.06M
- Book value per share
- $5.87
- Diluted shares
- 721M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$7.53M-67.6% YoY
Operating income
-$596.14M
Net income
-$266.25M
EPS, diluted
-$0.39
Free cash flow
-$821.06M
Reported periodTrailing twelve months